Dapagliflozin didn't significantly change the amount of fluid in the bloodstream of people with type 2 diabetes and healthy kidneys, even after two weeks of treatment.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design is nonrandomized and lacks a control group, so only association can be inferred. The claim correctly uses 'associated with' to reflect this limitation.

Evidence from Studies

Supporting (1)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Cohort Study

Human

2021 Feb

Contradicting (0)

No contradicting evidence found

Source Study

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Score: 44

DOI: 10.2337/dc20-2604

Similar Assertions

Dapagliflozin caused a temporary decrease in body fluid volume outside cells after 4 days, but this effect went away after two weeks in people with type 2 diabetes and healthy kidneys.

95%

Even though dapagliflozin lowered blood pressure, it didn't cause people with type 2 diabetes and healthy kidneys to excrete more salt in their urine when they ate a controlled amount of salt.

93%

Taking dapagliflozin for two weeks lowered blood pressure by about 6-7 points in people with type 2 diabetes and healthy kidneys, even when they ate a controlled amount of salt.

91%

People with type 2 diabetes and healthy kidneys lost about 0.8 kg after a few days and 1.8 kg after two weeks of taking dapagliflozin, likely due to water loss.

90%

As expected, dapagliflozin caused people with type 2 diabetes to excrete much more sugar in their urine, which is how the drug works to lower blood sugar.

88%